A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on December 7, 2025, with the following interim recommendations made:

• Acetaminophen and ibuprofen, when sold in oral, fixed-dose combinations, in package sizes containing either more than 20,000 mg of acetaminophen or more than 6,000 mg of ibuprofen remain in Schedule II, and

• Acetaminophen and ibuprofen, when sold in oral, fixed-dose combinations, in package sizes containing 20,000 mg or less of acetaminophen and 6,000 mg or less of ibuprofen remain in Schedule III

Any objections to these interim recommendations must be received by the NAPRA office by end of day January 14, 2026. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.